Increased soluble interleukin-2 receptor levels are related to somatic but not to cognitive-affective features in major depression

Brain, Behavior, and Immunity

Volumn 26, Issue 8, 2012, Pages 1244-1248

  Euteneuer, Frank ^a   Schwarz, Markus J ^b   Dannehl, Katharina ^a   Hartung, Anja ^a   Westermann, Stefan ^a   Rief, Winfried ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cognitive affective symptoms; Depression; Screening for somatoform symptoms self rating scale; Soluble interleukin 2 receptor; Soluble tumor necrosis factor receptor; Somatic symptoms; Somatoform symptoms

Indexed keywords

CYTOKINE RECEPTOR; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DSM-IV; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MOOD; PRIORITY JOURNAL; SOMATOFORM DISORDER;

ADULT; AFFECTIVE SYMPTOMS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; SOLUBILITY; SOMATOFORM DISORDERS;

EID: 84867208324     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.06.007     Document Type: Article

References (45)

1. Arnson Y., Shoenfeld Y., Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J. Autoimmun. 2010, 34:258-265.
2. Blum A., Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu. Rev. Med. 2001, 52:15-27.
3. Blume J., Douglas S.D., Evans D.L. Immune suppression and immune activation in depression. Brain Behav. Immun. 2011, 25:221-229.
4. Bosch N.M., Riese H.t., Dietrich A., Ormel J., Verhulst F.C., Oldehinkel A.J. Preadolescents' somatic and cognitive-affective depressive symptoms are differentially related to cardiac autonomic function and cortisol: the trails study. Psychosom. Med. 2009, 71:944-950.
5. Capuron L., Fornwalt F.B., Knight B.T., Harvey P.D., Ninan P.T., Miller A.H. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. J. Affect. Disord. 2009, 119:181-185.
6. Carney R.M., Freedland K.E. Are somatic symptoms of depression better predictors of cardiac events than cognitive symptoms in coronary heart disease?. Psychosom. Med. 2012, 74:33-38.
7. Caruso C., Candore G., Cigna D., Colucci A.T., Modica M.A. Biological significance of soluble IL-2 receptor. Mediators Inflamm. 1993, 2:3-21.
8. Creamer M., Foran J., Bell R. The Beck Anxiety Inventory in a non-clinical sample. Behav. Res. Ther. 1995, 33:477-485.
9. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
10. Diniz B.S., Teixeira A.L., Talib L.L., Mendonça V.A., Gattaz W.F., Forlenza O.V. Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. J. Psychiatr. Res. 2010, 44:917-920.
11. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
12. Enns M.W., Cox B.J., Parker J.D.A., Guertin J.E. Confirmatory factor analysis of the Beck Anxiety and Depression Inventories in patients with major depression. J. Affect. Disord. 1998, 47:195-200.
13. Euteneuer F., Schwarz M.J., Hennings A., Riemer S., Stapf T., Selberdinger V., Rief W. Psychobiological aspects of somatization syndromes: Contributions of inflammatory cytokines and neopterin. Psychiatry Res. 2012, 195:60-65.
14. Fox J. Regression Diagnostics: An Introduction 1991, Sage publications, Newbury Park.
15. Franke, G.H., 2000. Brief Symptom Inventory (BSI). Beltz, Göttingen.
16. Fuchs D., Avanzas P., Arroyo-Espliguero R., Jenny M., Consuegra-Sanchez L., Kaski J. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr. Med. Chem. 2009, 16:4644-4653.
17. Gameiro C., Romao F. Changes in the immune system during menopause and aging 2010, 1:1299-1303.
18. Grippo A.J., Johnson A.K. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress 2009, 12:1-21.
19. Hautzinger, M., Kühner, C., Keller, F., 2006. Das Beck Depressionsinventar II. Deutsche Bearbeitung und Handbuch zum BDI II. Harcourt Test Services, Frankfurt.
20. Hiller W., Zaudig M., Mombour W. IDCL - Internationale Diagnosen Checklisten f ü r ICD-10 und DSM-IV Hogrefe 1995, Göttingen.
21. Hoen P.W., Whooley M.A., Martens E.J., Na B., van Melle J.P., de Jonge P. Differential associations between specific depressive symptoms and cardiovascular prognosis in patients with stable coronary heart disease. J. Am. Coll. Cardiol. 2010, 56:838-844.
22. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Statist. 1979, 6:65-70.
23. Janssen D.G.A., Caniato R.N., Verster J.C., Baune B.T. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum. Psychopharmacol.: Clin Exp. 2010, 25:201-215.
24. Keaney J.F. Immune modulation of atherosclerosis. Circulation 2011, 124:e559-e560.
25. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Amp. Biobehav. Rev. 2012, 36:764-785.
26. Linke S.E., Rutledge T., Johnson B.D., Vaccarino V., Bittner V., Cornell C.E., Eteiba W., Sheps D.S., Krantz D.S., Parashar S., Bairey Merz C.N. Depressive symptom dimensions and cardiovascular prognosis among women with suspected myocardial ischemia: a report from the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation. Arch. Gen. Psychiatry 2009, 66:499-507.
27. Liu Y., Ho R.C.-M., Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-a) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J. Affect. Disord. 2012, 139:230-239.
28. Margraf J. Diagnostisches Kurzinterview bei psychischen Störungen [Diagnostic interview for mental disorders] (Mini-DIPS) Springer 1994, Heidelberg, New York, Berlin.
29. Margraf, J., Ehlers, A., 2000. Das Beck Angstinventar (BAI) deutsche Version. Testzentrale, Goettingen.
30. Mavreas V. The co-occurrence of depressive and anxiety disorders: results of a multi-national primary care study. Ann. Gen. Psychiatry 2006, 5:S18.
31. McNair, D., Lorr, M., Droppleman, L., 1981. POMS Profile of Mood States. Ein Verfahren zur Messung von Stimmungszuständen. In: Collegium Internationale Psychiatriae Scalarum (CIPS) (ed) Internationale Skalen für Psychiatrie. Beltz Test Gesellschaft, Weinheim.
32. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
33. ÓDonovan A., Hughes B.M., Slavich G.M., Lynch L., Cronin M.-T., ÓFarrelly C., Malone K.M. Clinical anxiety, cortisol and interleukin-6: Evidence for specificity in emotionâ€" biology relationships. Brain, Behav. Immun. 2010, 24:1074-1077.
34. Østergaard S.D., Jensen S.O.W., Bech P. The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatr. Scand. 2011, 124:495-496.
35. Rief W., Hennings A., Riemer S., Euteneuer F. Psychobiological differences between depression and somatization. J. Psychosom. Res. 2010, 68:495-502.
36. Rief W., Hiller W. A new approach to the assessment of the treatment effects of somatoform disorders. Psychosomatics 2003, 44:492-498.
37. Schiffer, Ang, lique, A., Pelle, Aline, J., Smith, Otto, R.F., Widdershoven, Jos, W., Hendriks, Eric, H., Pedersen, Susanne, S., 2009. Somatic Versus Cognitive Symptoms of Depression as Predictors of All-Cause Mortality and Health Status in Chronic Heart Failure. Physicians Postgraduate Press, Memphis, TN, ETATS-UNIS.
38. Singh T., Newman A.B. Inflammatory markers in population studies of aging. Ageing Res. Rev. 2010, 10:319-329.
39. Smolderen K.G., Spertus J.A., Reid K.J., Buchanan D.M., Krumholz H.M., Denollet J., Vaccarino V., Chan P.S. The Association of Cognitive and Somatic Depressive Symptoms With Depression Recognition and Outcomes After Myocardial Infarction. Cir.: Cardiovas. Qual. Outcomes 2009, 2:328-337.
40. Vaccarino A.L., Sills T.L., Evans K.R., Kalali A.H. Multiple pain complaints in patients with major depressive disorder. Psychosom. Med. 2009, 71:159-162.
41. Vikman K.S., Duggan A.W., Siddall P.J. Interferon-[gamma] induced disruption of GABAergic inhibition in the spinal dorsal horn in vivo. Pain 2007, 133:18-28.
42. Ward L.C. Comparison of Factor Structure Models for the Beck Depression Inventory-II. Psychol. Assess. 2006, 18:81-88.
43. Widner B., Laich A., Sperner-Unterweger B., Ledochowski M., Fuchs D. Neopterin production, tryptophan degradation, and mental depression: What is the link?. Brain Behav. Immun. 2002, 16:590-595.
44. Wieseler-Frank J., Maier S.F., Watkins L.R. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005, 14:166-174.
45. Zachar P., Kendler K.S. Psychiatric disorders: a conceptual taxonomy. Anglais 2007, 164:557-565.